155 related articles for article (PubMed ID: 37555463)
61. Eribulin mesylate in breast cancer.
Verdaguer H; Morilla I; Urruticoechea A
Womens Health (Lond); 2013 Nov; 9(6):517-26. PubMed ID: 24161305
[TBL] [Abstract][Full Text] [Related]
62. Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer.
Schwartzberg L; McIntyre K; Wilks S; Puhalla S; O'Shaughnessy J; Berrak E; He Y; Vahdat L
BMC Cancer; 2019 Jun; 19(1):578. PubMed ID: 31195996
[TBL] [Abstract][Full Text] [Related]
63. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer.
Twelves C; Cortes J; Vahdat LT; Wanders J; Akerele C; Kaufman PA
Clin Breast Cancer; 2010 Apr; 10(2):160-3. PubMed ID: 20299316
[TBL] [Abstract][Full Text] [Related]
64. Vinorelbine After Prior Treatment With Eribulin for Advanced Breast Cancer: A Single-Centre Experience Suggesting Cross-Resistance.
Okines AFC; Irfan T; Mohammed K; Ring A; Parton M; Kipps E; Johnston S; Turner NC
Clin Breast Cancer; 2022 Oct; 22(7):e825-e831. PubMed ID: 35840514
[TBL] [Abstract][Full Text] [Related]
65. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
Scarpace SL
Clin Ther; 2012 Jul; 34(7):1467-73. PubMed ID: 22739019
[TBL] [Abstract][Full Text] [Related]
66. Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study).
Yamashita T; Kawaguchi H; Masuda N; Kitada M; Narui K; Hattori M; Yoshinami T; Matsunami N; Yanagihara K; Kawasoe T; Nagashima T; Bando H; Yano H; Hasegawa Y; Nakamura R; Kashiwaba M; Morita S; Ohno S; Toi M
Invest New Drugs; 2021 Feb; 39(1):217-225. PubMed ID: 32833136
[TBL] [Abstract][Full Text] [Related]
67. Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11).
Kim JY; Park S; Im SA; Kim SB; Sohn J; Lee KS; Chae YS; Lee KH; Kim JH; Im YH; Kim TY; Lee KH; Ahn JH; Kim GM; Park IH; Lee SJ; Han HS; Kim SH; Jung KH; Park YH;
Cancer Commun (Lond); 2019 May; 39(1):29. PubMed ID: 31138332
[TBL] [Abstract][Full Text] [Related]
68. Eribulin-induced liver dysfunction as a prognostic indicator of survival of metastatic breast cancer patients: a retrospective study.
Kobayashi T; Tomomatsu J; Fukada I; Shibayama T; Teruya N; Ito Y; Iwase T; Ohno S; Takahashi S
BMC Cancer; 2016 Jul; 16():404. PubMed ID: 27389013
[TBL] [Abstract][Full Text] [Related]
69. Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study.
Kikawa Y; Kotake T; Tsuyuki S; Kang Y; Takahara S; Fujimoto Y; Yamashiro H; Yoshibayashi H; Takada M; Yasuoka R; Nakatsukasa K; Yamagami K; Suwa H; Okuno T; Nakayama I; Kato T; Ogura N; Moriguchi Y; Ishiguro H; Kagimura T; Taguchi T; Sugie T; Toi M
Breast Cancer; 2022 Sep; 29(5):796-807. PubMed ID: 35460066
[TBL] [Abstract][Full Text] [Related]
70. Eribulin for the treatment of advanced or metastatic breast cancer: a NICE single technology appraisal.
Greenhalgh J; Bagust A; Boland A; Oyee J; Trevor N; Beale S; Dundar Y; Hockenhull J; Proudlove C; O'Reilly S
Pharmacoeconomics; 2015 Feb; 33(2):137-48. PubMed ID: 25213036
[TBL] [Abstract][Full Text] [Related]
71. Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial.
Tolaney SM; Barroso-Sousa R; Keenan T; Li T; Trippa L; Vaz-Luis I; Wulf G; Spring L; Sinclair NF; Andrews C; Pittenger J; Richardson ET; Dillon D; Lin NU; Overmoyer B; Partridge AH; Van Allen E; Mittendorf EA; Winer EP; Krop IE
JAMA Oncol; 2020 Oct; 6(10):1598-1605. PubMed ID: 32880602
[TBL] [Abstract][Full Text] [Related]
72. Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial.
Pérez-García JM; Llombart-Cussac A; G Cortés M; Curigliano G; López-Miranda E; Alonso JL; Bermejo B; Calvo L; Carañana V; de la Cruz Sánchez S; M Vázquez R; Prat A; R Borrego M; Sampayo-Cordero M; Seguí-Palmer MÁ; Soberino J; Malfettone A; Schmid P; Cortés J
Eur J Cancer; 2021 May; 148():382-394. PubMed ID: 33794440
[TBL] [Abstract][Full Text] [Related]
73. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial.
Cortes J; Hudgens S; Twelves C; Perez EA; Awada A; Yelle L; McCutcheon S; Kaufman PA; Forsythe A; Velikova G
Breast Cancer Res Treat; 2015 Dec; 154(3):509-20. PubMed ID: 26567010
[TBL] [Abstract][Full Text] [Related]
74. Eribulin efficacy based on type of metastatic site: a real-life study in heavily pretreated metastatic breast cancer.
Prestifilippo A; Grippaldi D; Blanco G; Memeo L; Puliafito I; Giuffrida D
Future Oncol; 2017 Apr; 13(11s):5-10. PubMed ID: 28481186
[TBL] [Abstract][Full Text] [Related]
75. [Multicenter real world study on the efficacy and safety of eribulin for the treatment of advanced breast cancer].
Sang D; Song LH; Di LJ; Wang YL; Liu CG; Guo ZQ; Liu QY; Wang H; Li SY; Yuan P
Zhonghua Zhong Liu Za Zhi; 2022 Apr; 44(4):364-369. PubMed ID: 35448926
[No Abstract] [Full Text] [Related]
76. Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study.
Oruc Z; Kaplan MA; Geredeli C; Yildirim Sari N; Ozaslan E; Aytekin A; Tamer Elkiran E; Koca S; Dogan M; Turan N; Yuce O; Sevinc A; Ercelep O; Isikdogan A
J BUON; 2019; 24(5):1876-1883. PubMed ID: 31786850
[TBL] [Abstract][Full Text] [Related]
77. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial.
Yuan P; Hu X; Sun T; Li W; Zhang Q; Cui S; Cheng Y; Ouyang Q; Wang X; Chen Z; Hiraiwa M; Saito K; Funasaka S; Xu B
Eur J Cancer; 2019 May; 112():57-65. PubMed ID: 30928806
[TBL] [Abstract][Full Text] [Related]
78. Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer.
Kashiwagi S; Fukushima W; Asano Y; Goto W; Takada K; Noda S; Takashima T; Onoda N; Ohsawa M; Hirakawa K; Ohira M
BMC Cancer; 2017 Aug; 17(1):604. PubMed ID: 28859615
[TBL] [Abstract][Full Text] [Related]
79. Efficacy and safety of eribulin in taxane-refractory patients in the 'real world'.
Lorusso V; Cinieri S; Latorre A; Porcu L; Del Mastro L; Puglisi F; Barni S
Future Oncol; 2017 May; 13(11):971-978. PubMed ID: 28326833
[TBL] [Abstract][Full Text] [Related]
80. Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center.
Sirvén MB; Fernández-Ortega A; Stradella A; Morilla I; Falo C; Vázquez S; Castany R; Villanueva R; Recalde S; Pérez VN; Gil-Gil M; Pernas S
BMC Pharmacol Toxicol; 2019 Nov; 20(1):68. PubMed ID: 31753013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]